{"id":13618,"date":"2022-11-03T11:14:52","date_gmt":"2022-11-03T10:14:52","guid":{"rendered":"https:\/\/www.mybits.de\/development-of-a-web-application-and-a-mobile-app-to-improve-breast-cancer-patient-follow-up\/"},"modified":"2024-11-13T18:44:45","modified_gmt":"2024-11-13T17:44:45","slug":"development-of-a-web-application-and-a-mobile-app-to-improve-breast-cancer-patient-follow-up","status":"publish","type":"post","link":"https:\/\/www.mybits.de\/en\/development-of-a-web-application-and-a-mobile-app-to-improve-breast-cancer-patient-follow-up\/","title":{"rendered":"Development of a web application and a mobile app to improve breast cancer patient follow-up.<\/b>"},"content":{"rendered":"

Development of a web application and a mobile app to improve breast cancer patient follow-up.<\/h1>\n<\/div>

Together with AIM-Apps in Medicine GmbH<\/a>, AOK Bayern<\/a>, DAK Gesundheit<\/a> and Siemens Betriebskrankenkasse (SBK)<\/a>, under the direction of the Klinikum rechts der Isar of the Technical University of Munich (MRI)<\/a>, BITS GmbH participated in the PRISMA study<\/a> as a consortium partner for the technical infrastructure and developed the PRISMA portal<\/a> and the “Meine Busenfreundin” app<\/a> for this purpose. Thirty breast centers throughout Bavaria are participating in the associated study. PRISMA is funded with 3.46 million from the Innovation Fund of the Federal Joint Committee (GBA)<\/a>.<\/p>\n<\/div>

\"it<\/span><\/div>

The tasks of BITS here include all digital aspects, including technical IT project management, IT conception, IT architecture and development of the web portal to manage the study and the implementation of the digital questionnaires within the app “Meine Busenfreundin”.<\/p>\n<\/div>

<\/i><\/span><\/div>

100% digitization<\/h2><\/div>
<\/div>
\n

Establishment of the digital infrastructure for conducting the study<\/p>\n<\/div><\/div><\/div>

<\/i><\/span><\/div>

100% web & mobile<\/h2><\/div>
<\/div>
\n

Web-based portal platform and mobile app for Android and iOS<\/p>\n<\/div><\/div><\/div>

<\/i><\/span><\/div>

Interfaces & Alarms<\/h2><\/div>
<\/div>
\n

Interfaces to external systems and information about anomalies<\/p>\n<\/div><\/div><\/div>

<\/div><\/div>
<\/i><\/span><\/div>

100% web & mobile<\/h2><\/div>
<\/div>
\n

Web-based platform for browsers and mobile apps<\/p>\n<\/div><\/div><\/div>

<\/i><\/span><\/div>

100% SEO optimized<\/h2><\/div>
<\/div>
\n

Ongoing optimization for page 1 on Google<\/p>\n<\/div><\/div><\/div>

<\/i><\/span><\/div>

100% digitization<\/h2><\/div>
<\/div>
\n

We are digitizing a previously analog industry<\/p>\n<\/div><\/div><\/div>

<\/div><\/div><\/div><\/div><\/div><\/div>

BITS as consortium partner<\/h2>\n<\/div>
\n

“Together with BITS GmbH as technical partner for the development of the PRISMA portal and mobile app, we have successfully started the PRISMA study. We want to use this new form of care to improve the quality of life and treatment adherence of breast cancer patients.”<\/em><\/p>\n<\/div><\/div><\/span><\/blockquote>

\"ProfDrMarionKiechle<\/span>Prof. Dr. Marion Kiechle<\/strong>, <\/span>Director of the Gynecological Clinic at the Klinikum rechts der Isar of the Technical University of Munich<\/span><\/span><\/div><\/div><\/div><\/div><\/div><\/div>
\"a<\/span><\/div><\/div><\/div><\/div><\/div><\/div>

BITS as consortium partner<\/h2>\n<\/div>
\n

“Together with BITS GmbH as technical partner for the development of the PRISMA portal and mobile app, we have successfully started the PRISMA study. We want to use this new form of care to improve the quality of life and treatment adherence of breast cancer patients.”<\/em><\/p>\n<\/div><\/div><\/span><\/blockquote>

\"ProfDrMarionKiechle<\/span>Prof. Dr. Marion Kiechle<\/strong>, <\/span>Director of the Gynecological Clinic at the Klinikum rechts der Isar of the Technical University of Munich<\/span><\/span><\/div><\/div><\/div><\/div><\/div><\/div>
\"a<\/span><\/div><\/div><\/div><\/div><\/div><\/div>

Challenge<\/h2>\n<\/div><\/div><\/div>
\n

Breast cancer is one of the most common cancers in women, with around 70,000 new cases each year. In most cases, for women with hormone-sensitive breast cancer, treatment is not over even after surgery, chemotherapy and radiation therapy. This is followed by years of taking medication, because with the appropriate anti-hormone therapy, the risk of relapse can be halved. Nevertheless, many women discontinue the medication within the first two years.<\/p>\n<\/div>\n

\n

The reasons for this are the great psychological stress caused by the disease and the side effects caused by taking the medication.<\/p>\n

This is where PRISMA (primary hormone-sensitive breast carcinoma) comes in. The goal is to provide patients with new digital, on-demand care to prevent the risk of relapse.<\/p>\n<\/div>\n<\/div>